54 results
8-K
EX-10.1
CPRX
Catalyst Pharmaceuticals Inc
23 Jun 23
Catalyst Pharmaceuticals to License North American Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
4:31pm
or activity, design, source code, business plan, business opportunity, customer or personnel list, or financial statement proprietary to the Disclosing Party
8-K/A
EX-99.1
ek8uv4u j4jzdi7ey
10 Apr 23
Financial Statements and Exhibits
4:30pm
8-K
EX-2.1
ba4uiy27y9he40rp
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.1
w11sh4h9
22 Dec 22
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
4:31pm
8-K
EX-10.1
ghxl4iu2f9djy mqp5g
30 Jun 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
1voqitv918hmr
20 Aug 20
Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada
5:15pm